Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH) is a common long-term complication of pulmonary embolism characterized by thromboembolic obstruction of the pulmonary arteries, vascular arteriopathy, vascular remodeling, and ultimately pulmonary hypertension (PH). Although pulmonary endarterectomy (PEA) surgery is the standard of care, approximately 40% of patients in the international CTEPH registry were deemed inoperable. In addition to lifelong anticoagulation, the cornerstone of PH-specific medical management is riociguat, a soluble guanylate cyclase stimulator. Medical management should be started early in CTEPH patients and may be used as a bridge to PEA surgery or balloon pulmonary angiography. Medical management is indicated for inoperable CTEPH patients and patients who have recurrence of PH after PEA surgery.
Original language | English (US) |
---|---|
Pages (from-to) | e29-e33 |
Journal | Methodist DeBakey cardiovascular journal |
Volume | 17 |
Issue number | 2 |
DOIs | |
State | Published - 2021 |
Keywords
- CTEPH
- chronic thromboembolic pulmonary hypertension
- pulmonary embolism
- pulmonary endarterectomy
- riociguat
- Hypertension, Pulmonary/diagnosis
- Pulmonary Artery/diagnostic imaging
- Pulmonary Embolism/diagnosis
- Humans
- Endarterectomy/adverse effects
- Chronic Disease
ASJC Scopus subject areas
- General Medicine